CMH Wealth Management LLC cut its stake in Amgen, Inc. (NASDAQ:AMGN) by 1.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,608 shares of the medical research company’s stock after selling 260 shares during the period. Amgen comprises approximately 1.9% of CMH Wealth Management LLC’s portfolio, making the stock its 16th largest position. CMH Wealth Management LLC’s holdings in Amgen were worth $2,367,000 at the end of the most recent reporting period.
Other large investors have also made changes to their positions in the company. Camelot Portfolios LLC purchased a new position in Amgen during the first quarter worth about $1,429,000. PGGM Investments grew its position in Amgen by 2.3% during the second quarter. PGGM Investments now owns 670,936 shares of the medical research company’s stock worth $115,555,000 after buying an additional 15,059 shares during the period. Shelton Capital Management grew its position in Amgen by 82.7% during the first quarter. Shelton Capital Management now owns 108,997 shares of the medical research company’s stock worth $17,883,000 after buying an additional 49,354 shares during the period. Cadence Bank NA grew its position in Amgen by 6.2% during the first quarter. Cadence Bank NA now owns 3,376 shares of the medical research company’s stock worth $554,000 after buying an additional 197 shares during the period. Finally, Telos Capital Management Inc. grew its position in Amgen by 1.6% during the first quarter. Telos Capital Management Inc. now owns 14,348 shares of the medical research company’s stock worth $2,354,000 after buying an additional 227 shares during the period. 78.14% of the stock is owned by institutional investors and hedge funds.
Amgen, Inc. (AMGN) traded down 0.98% during trading on Friday, reaching $187.59. 3,240,437 shares of the company traded hands. The company has a market cap of $136.88 billion, a PE ratio of 17.09 and a beta of 1.35. Amgen, Inc. has a 12 month low of $133.64 and a 12 month high of $191.10. The company’s 50-day moving average is $174.87 and its 200 day moving average is $169.24.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. The business had revenue of $5.81 billion for the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a return on equity of 27.67% and a net margin of 37.02%. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.84 EPS. On average, analysts anticipate that Amgen, Inc. will post $12.57 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Thursday, August 17th were issued a dividend of $1.15 per share. The ex-dividend date was Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a yield of 2.43%. Amgen’s dividend payout ratio (DPR) is 41.93%.
A number of analysts recently issued reports on the stock. Royal Bank Of Canada assumed coverage on shares of Amgen in a research report on Thursday. They set a “sector perform” rating and a $192.00 target price on the stock. Cann restated a “buy” rating and set a $203.00 target price (up previously from $189.00) on shares of Amgen in a research report on Wednesday, July 26th. BMO Capital Markets downgraded shares of Amgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, July 26th. Deutsche Bank AG reaffirmed a “hold” rating and set a $174.00 price target (up previously from $172.00) on shares of Amgen in a research note on Wednesday, July 26th. Finally, Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $203.00 price target (up previously from $189.00) on shares of Amgen in a research note on Wednesday, July 26th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. Amgen currently has a consensus rating of “Buy” and an average target price of $186.14.
COPYRIGHT VIOLATION WARNING: “CMH Wealth Management LLC Sells 260 Shares of Amgen, Inc. (NASDAQ:AMGN)” was reported by BBNS and is the property of of BBNS. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://baseballnewssource.com/markets/amgen-inc-amgn-position-lowered-by-cmh-wealth-management-llc/1605304.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with our FREE daily email newsletter.